Liposomal cytarabine and daunorubicin (CPX-351) for treatment of acute myeloid leukemia

References

• Estey E, Döhner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907.
   Google Scholar
• Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood. 2010;116(17):3147–3156.
   Google Scholar
• Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Am Soc Hematol – Hematol Educ Program. 2012;2012:1–6.
   Google Scholar
• Estey E. Why is progress in acute myeloid leukemia so slow? Semin Hematol. 2015 Jul;52(3):243–248.
   Google Scholar
• Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982;60(2):454–462.
   Google Scholar
• Ravandi F. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia? Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3–4):241–246.
   Google Scholar
• Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013;381:484–495.
   Google Scholar
• Rowe JM. The impact of mutational profiling on AML prognosis. Best Pract Res Clin Haematol. 2012;25(4):403–408.
   Google Scholar
• Burnett A, Wetzler M, Löwenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494.
   Google Scholar
• Rowe JM. Optimal induction and postremission therapy for AML in first remission. Hematology Am Soc Hematol Educ Program. 2009;396–405.
   Google Scholar
• Schlenk RF. Postremission therapy for acute myeloid leukemia. Haematologica. 2014;99:1663–1670.
   Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   Google Scholar
• Kantarjian H, O’Brien S. Questions regarding frontline therapy of acute myeloid leukemia. Cancer. 2010;116:4896–4901.
   Google Scholar
• Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.
   Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. UK National Cancer Research Institute AML working group. assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016 Feb 4;374(5):422–433.
   Google Scholar
• Oran B, Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica. 2012;97(12):1916–1924.
   Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   Google Scholar
• Thomas X, Le Jeune C. The safety of treatment options for elderly people with acute myeloid leukemia. Expert Opin Drug Saf. 2016 Mar;17:1–11.
   Google Scholar
• Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–774.
   Google Scholar
• Sanford D, Ravandi F. Management of newly diagnosed acute myeloid leukemia in the elderly: current strategies and future directions. Drugs Aging. 2015;32(12):983–997.
   Google Scholar
• Ravandi F, Ritchie EK, Sayar H, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomized, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–1036.
   Google Scholar
• Kropf P, Jabbour E, Yee K, et al. Late responses and overall survival (OS) from long term follow up of a randomized phase II study of SGI-110 (guadecitabine) 5-day regimen in elderly AML who are not eligible for intensive chemotherapy. 20th Congress of the European Hematology Association; 2015 June 11-14; Vienna, Austria. Abstract P571.
   Google Scholar
• Döhner H, Lübbert M, Fiedler W, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124(9):1426–1433.
   Google Scholar
• Stein EM, Stein A, Walter RB, et al. Interim analysis of a phase I trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML). Blood. 2014;124:623; abstract.
   Google Scholar
• Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687.
   Google Scholar
• Daver N, Konopleva M. Sorafenib and novel multikinase inhibitors in AML. Lancet Oncol. 2015;16(16):1582–1583.
   Google Scholar
• Randhawa JK, Kantarjian HM, Borthakur G, et al. Results of a Phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients with activating FLT3 mutations. Blood. 2014;124(21) :389.
   Google Scholar
• Levis MJ, Perl AE, Altman JK, et al. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). J Clin Oncol. 2015;33(abstract):7003.
   Google Scholar
• Stone RM, Mandrekar S, Sanford MS, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine © induction (ind), high-Dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603 /RATIFY [Alliance]). Blood. 2015;126:6. ASH abstract 6.
   Google Scholar
• Kühn MW, Hadler MJ, Daigle SR, et al. Haematologica. 2015;100(5):e190–3.
   Google Scholar
• Konopleva M, Pollyea DA, Potluri J, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (ALM). Blood. 2014;124(21) :118.
   Google Scholar
• Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–184.
   Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010. 1. 28(22):3636–3643.
   Google Scholar
• Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;ASH 126:323; abstract.
   Google Scholar
• Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine. 2014 Jan;15(9):467–483.
   Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52–79.
   Google Scholar
• Hyodo K, Yamamoto E, Suzuki T, et al. Development of liposomal anticancer drugs. Biol Pharm Bull. 2013;36:703–707.
   Google Scholar
• Stylianopoulos T, Jain RK. Design considerations for nanotherapeutics in oncology. Nanomedicine. 2015;11(8):1893–1907.
   Google Scholar
• Nakamura H, Jun F, Maeda H. Development of next generation macromolecular drugs based on the EPR effect: challenges and pitfalls. Expert Opin Drug Deliv. 2015;12:53–64.
   Google Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33:129–139.
   Google Scholar
• Feldman EF, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine: daunorubicin,in patients with advanced leukemia. Leuk Res. 2012;36(10):1283–1289.
   Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine-daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34:1214–1223.
   Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a Fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29:979–985.
   Google Scholar
• Danesi R, Fogli S, Gennari A, et al. Pharmacokinetics-pharmacodynamic relationships of the anthracycline anticancer drugs. Clinical Pharmacokinets. 2002;41(6):431–444.
   Google Scholar
• Dampath D, Cortes J, Estrov Z, et al. Pharamacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107(6):2517–2524.
   Google Scholar
• Lancet JE, Cortes JE, Hogge D, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246.
   Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121:234–242.
   Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. Final Results of a Phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high-risk (Secondary) AML. J Clin Onc. 2016;34:7000. (abstract)
   Google Scholar
• Lowenberg B, Ossendoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248.
   Google Scholar
• Stein EM, Tallman MS. Emerging therapeutic drugs for AML. Blood. 2016;127:71–78.
   Google Scholar